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Introduction
Rheumatoid arthritis (RA) is a common human disease,
with a prevalence of about 1%. The clinical presentation is
heterogeneous, with a wide spectrum of age of onset,
degree of joint involvement, and severity. Up to 90% of
patients with aggressive synovitis have radiologic evi-
dence of bone erosion within 2 years of diagnosis, despite
treatment [1]. However, at the onset of symptoms, it is dif-
ficult to predict which patients will follow a more severe
disease course. It is now highly desirable to identify such
patients at an early stage in their disease evolution,
because of the advent of biologic agents that have the
potential not only to significantly improve symptoms and
signs of disease in a high proportion of patients [2], but
also to arrest structural damage to joints [3]. At present,
the economic burden of these new therapies is such that
rationing of some sort is inevitable and it is therefore
equally desirable to determine whether those patients
receiving biologic therapies are responding adequately at
an early stage of their treatment.
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Chapter summary
Angiogenesis is a prominent feature of rheumatoid synovitis. Formation of new blood vessels permits a
supply of nutrients and oxygen to the augmented inflammatory cell mass and so contributes to
perpetuation of joint disease. Vascular endothelial growth factor (VEGF) is a potent endothelial cell-
specific growth factor that is upregulated by proinflammatory cytokines and by hypoxia. Serum VEGF
concentrations are elevated in rheumatoid arthritis (RA) and correlate with disease activity.
Furthermore, serum VEGF measured at first presentation in RA is highly significantly correlated with
radiographic progression of disease over the subsequent year. Power Doppler ultrasonography is a
sensitive method for demonstrating the presence of blood flow in small vessels and there is a very
close relation between the presence or absence of vascular flow signal on power Doppler imaging and
the rate of early synovial enhancement on dynamic gadolinium-enhanced magnetic resonance imaging
(MRI) of joints with RA. Images obtained by both dynamic enhanced MRI and power Doppler
ultrasonography correlate with vascularity of synovial tissue as assessed histologically. In early RA,
there is a striking association between joint erosions assessed on high-resolution ultrasonography and
vascular signal in power Doppler mode. Collectively, these findings implicate vascular pannus in the
erosive phase of disease and strongly suggest that proangiogenic molecules such as VEGF are
targets for novel therapies in RA. Animal model data supports this concept. It seems likely that
serological and imaging measures of vascularity in RA will become useful tools in the assessment of
disease activity and response to therapy.
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In health, angiogenesis — or growth of new blood vessels
from pre-existing vasculature — occurs during growth and
the female reproductive cycle. It is also a feature of tissue
repair after injury and contributes to the pathogenesis of a
number of disease states, including cancer, chronic gin-
givitis, diabetic retinopathy, and RA. Angiogenesis occurs
as a coordinated process comprising proliferation and
migration of endothelial cells, followed by the formation of
capillary tubes, deposition of basement membrane, and
proliferation and migration of pericytes and smooth
muscle cells. Anastomoses are created and flow of blood
is established. Vascular reorganisation follows, in a
process requiring the regression of redundant vessels by
apoptosis of endothelial cells [4]. In order to match func-
tion of the microvascular bed to local metabolic demand,
the developing vessels begin to express vasoactive pep-
tides and their receptors [5].
Angiogenesis in the synovial membrane of patients with
RA is considered by many investigators to be an important
early step in pathogenesis of RA and in the perpetuation
of disease [5,6]. This chapter focuses on recent research
findings arising from serologic and imaging measures of
vascularity in RA. I discuss the role of vascular endothelial
growth factor (VEGF), a marker of angiogenesis, in the
pathophysiology of RA, and emerging evidence that serum
VEGF concentrations correlate with disease activity and
fall when synovitis is successfully suppressed by therapy. I
will also discuss the potential of angiogenic markers, such
as VEGF, to predict disease outcome. I review develop-
ments in imaging technologies that permit assessment of
synovial vascularity and discuss their potential application
in the evaluation of RA disease activity, prediction of
disease progression, and monitoring of response to
therapy. I examine the implications of these findings for our
understanding of disease pathogenesis and consider the
potential of VEGF and angiogenesis as a target for therapy.
Historical background: the role of VEGF in RA
Angiogenesis, regulated by a complex set of inducers and
inhibitors, arises when hypoxic, diseased, or injured
tissues secrete proangiogenic molecules. Many endothe-
lial growth factors have been demonstrated in RA syn-
ovium [6–8] and tenosynovium [9]. Of these, VEGF is the
most endothelial-cell-specific factor characterised to date
[10–12]. It also induces vascular permeability [13]. In RA
synovium, VEGF expression is upregulated in
macrophages and fibroblasts [14,15] and we have
demonstrated protein expression in synovial endothelial
cells by immunohistochemistry [16] (Fig. 1). Co-culture of
activated monocytes or neutrophils from RA synovial fluids
with unstimulated, semiconfluent RA fibroblast-like syn-
oviocytes results in synergistic increases in the expression
and secretion of bioactive VEGF [17]. Furthermore, this
induction of VEGF is significantly inhibited by anti-integrin
antibodies, a finding implying that VEGF expression in RA
synovitis is regulated not only by proinflammatory
cytokines, but also by the physical interaction of activated
leukocytes and fibroblast-like synoviocytes [17].
VEGF exists as several isoforms, generated by alternative
splicing of VEGF mRNA. RT-PCR analysis shows the
VEGF(121) isoform to be expressed constitutively in RA syn-
ovial tissues, whereas the VEGF(165) isoform is expressed
in less than half the tissues examined [18,19]. Microvascular
density is significantly higher in RA synovial tissues express-
ing VEGF(165) [18]. The proportion of microvessels
expressing CD31 that are activated, as assessed by a mono-
clonal antibody recognising the VEGF/KDR receptor
complex, is significantly greater in RA than in osteoarthritis or
normal synovial tissue [20]. VEGF receptor Flt-1 (VEGFR-1)
protein is expressed on microvessels in close proximity to
VEGF protein [19] and there is a close correlation between
expression of isoform VEGF(165) and that of its receptors
KDR (VEGFR-2) and neuropilin [18].
In the case of inflammatory tissue, several interdependent
processes promote angiogenesis. Shear stress on the
endothelial wall as a result of increased blood flow may
enhance angiogenesis, as may extravasated plasma pro-
teins such as fibrinogen products. Similarly, inflammatory
cells — including macrophages, lymphocytes, mast cells,
and fibroblasts — and their proangiogenic soluble prod-
ucts promote angiogenesis. Many cytokines promoting
inflammation, such as tumour necrosis factor (TNF)-α, IL-
1, and IL-8 also have proangiogenic activity. Hypoxia,
which is often a feature of inflammation, is a potent
inducer of VEGF. Furthermore, hypoxic culture conditions
greatly augment the rate of VEGF secretion from cultured
synovial fibroblasts stimulated by IL-1 and transforming
growth factor (TGF)-β [21]. Direct measurements confirm
that the RA joint is a hypoxic environment [22]. Contribu-
tory factors include the high metabolic demands of
Figure 1
Staining of rheumatoid synovium for vascular endothelial growth factor,
showing expression of the factor in endothelial cells.S101
inflamed synovial tissue and the rapid rate of synovial pro-
liferation, such that cells become more distant from the
closest blood vessels, compounding the hypoxic state
[23]. Tissue hypoxia in the rheumatoid joint results in
increased VEGF mRNA stability [24] and enhances VEGF
gene transcription through the binding of hypoxia-
inducible transcription factors such as HIF-1 and HIF-2.
Both of these factors are degraded within minutes of
exposure to an oxygen tension >3–5% but are stabilised
under conditions of hypoxia (<3% oxygen), then translo-
cated to the nucleus, where they bind to hypoxia-respon-
sive elements on hypoxia-inducible genes to upregulate
their expression [25]. Thus, it is possible that the hypoxic
environment in the rheumatoid joint, compounded by the
high metabolic demands of synovial inflammation, pro-
motes transcriptional changes permissive to perpetuation
of synovitis.
Measuring VEGF in RA: relation to disease
activity and response to therapy
VEGF is detectable in serum, synovial tissue, and fluids of
patients with RA [14,15,26–30]. Human neutrophils
secrete VEGF [31], and Kasama et al. report that concen-
trations of neutrophil-associated VEGF in RA synovial
fluids correlate well with free VEGF in joint effusions and
with the patient’s disease activity [32]. Other investigators
find no correlation between VEGF concentrations in
serum and synovial fluids from the same RA patients [33].
Synovial fluid VEGF concentrations correlate with matrix
metalloproteinase (MMP)-9 concentrations in the fluid in
early inflammatory arthritis [34].
The source of VEGF in the serum is unclear. In vitro,
human peripheral blood mononuclear cells have been
shown to release VEGF in response to cytokines
expressed in RA synovium, such as TNF-α [29]. Release
of VEGF from platelets has also been reported [35].
Serum VEGF might therefore be derived from platelets,
synovial-fluid neutrophils, inflamed synovial tissue, or other
sources.
A number of groups have reported that VEGF concentra-
tions are higher in the serum of RA patients than in healthy
controls or patients with osteoarthritis [27,33,35–37]. Fur-
thermore, serum VEGF concentrations correlate with indi-
vidual and composite measures of RA disease activity,
including acute phase markers and counts of swollen and
tender joints [33,36,37]. In a study of patients attending
my early clinics for inflammatory arthritis and established
RA, serum VEGF concentrations were higher in patients
with early RA than in patients with long-standing, treated
RA [36]. This observation may represent a response to
therapy, a view supported by studies in which serum
VEGF concentrations have been measured before and
after commencement of therapy [27,35,36]. In our series,
a total of 27 early RA patients responsive to DMARD
(disease-modifying antirheumatic drug) therapy exhibited a
significant reduction in serum VEGF concentrations, in
contrast to patients unresponsive to DMARD treatment,
who showed no such significant change [36]. Treatment
of RA patients with anti-TNF-α therapy results in marked
reduction, but not normalisation, of serum VEGF concen-
trations [38]. The correlation of this reduction with
changes in clinical and laboratory measures of disease
activity suggests that the diminished vascular permeability
consequent upon reduced VEGF concentrations con-
tributes to the rapid decrease in counts of swollen joints
observed after TNF blockade.
The significant reductions in serum VEGF concentrations
following response to therapy in RA suggest that angio-
genesis is an important process in perpetuating synovitis
and raises the possibility that persistence of joint inflam-
mation indicates an imbalance between inducers and
inhibitors of angiogenesis. This concept is supported by
the observation that concentrations of endostatin, an
angiogenesis inhibitor, are not elevated in serum and syn-
ovial fluid samples from patients in whom serum VEGF is
elevated [35]. Another naturally occurring inhibitor of
angiogenesis is soluble Flt-1, a VEGF antagonist. Soluble
Flt-1 (sFlt-1) is an alternatively spliced form of Flt-1, one of
the tyrosine kinase receptors that mediate the action of
VEGF [12,39,40]. We found that sFlt-1 is higher in groups
with both early and long-standing RA than in controls, and
that elevated sFlt-1 concentrations correlate with VEGF
concentrations in serum of the same RA patients [36]. The
raised concentrations of sFlt-1 observed in RA are pre-
sumably insufficient to inhibit VEGF activity. This finding is
analogous to reports in RA of elevated concentrations of
other proinflammatory cytokines and their naturally occur-
ring inhibitors.
Can angiogenic markers predict disease
outcome?
My colleagues and I have recently reported that serum
VEGF concentrations at presentation with early RA corre-
late highly significantly with development of radiographic
damage over the subsequent year [36] as assessed in
radiographs of the hands and feet by the van der Heijde
modification of Sharp’s method [41] (Fig. 2). We have
also observed that RA patients with persistent disease
activity despite conventional therapy have relatively high
serum VEGF concentrations at first presentation. If con-
firmed in larger series, these observations would support
the case for early introduction of a more aggressive thera-
peutic regime in patients with highly elevated serum VEGF
concentrations early in their disease course. It might also
be speculated that, in the future, serial serum measure-
ments of angiogenic markers may help to determine
whether vascular pannus, with its potential to cause carti-
lage and bone destruction, is adequately suppressed at
any given stage of disease evolution.
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Techniques for imaging synovial vasculature
in RA
Blood flows at high velocity in large vessels and can be
readily detected by conventional colour Doppler sonogra-
phy, which encodes the mean Doppler frequency shift.
However, at the microvascular level, which is of interest
with respect to rheumatoid synovitis, blood flow is at lower
velocities that are less readily detectable by conventional
colour Doppler sonography. Power Doppler sonography,
on the other hand, encodes the amplitude of the power
spectral density of the Doppler signal and is a sensitive
method for demonstrating the presence of blood flow in
small vessels. Several recent studies have demonstrated
that power Doppler ultrasound is capable of detecting
inflammatory hyperaemia in RA synovitis [42–46]. Further-
more, the signal intensity on power Doppler imaging of
synovitis in rheumatoid knee joints correlates well with the
histologic assessment of synovial membrane microvascu-
lar density in tissue taken at arthroplasty from the previ-
ously imaged site [45]. Quantitative assessment of
vascularised synovium in metacarpophalangeal joints of
patients with RA, as demonstrated by power Doppler, has
been reported to correlate with ESR [47]. However, in this
cohort of RA patients in the established phase of disease
(mean 7.6 years), there was no preponderance of blood
flow near joint erosions. In contrast, in a cohort of 39
patients with early RA (disease duration <3 years), we
have observed a striking association between the pres-
ence of bone erosion in metacarpophalangeal joints and
increased intra-articular blood flow at the site of bone
damage [48] (Fig. 3). This finding is consistent with the
hypothesis that vascularity is associated with the active
phase of erosive disease. Laser Doppler imaging of
metacarpophalangeal joints in RA has also been reported
to correlate with pain scores and synovitis detected on
grey-scale high-resolution ultrasound [49]. As disease in
many patients with RA continues to progress in spite of
suppression of clinically evident synovitis, these noninva-
sive tools will enhance our ability to detect active vascu-
larised synovium and may also therefore influence the use
of DMARD and biologic therapies in such patients.
We have investigated the capability of power Doppler and
high-resolution ultrasound imaging to discriminate
between patients receiving infliximab or placebo infusions
added to pre-existing methotrexate treatment over the first
18 weeks of therapy in a clinical trial [50]. Median reduc-
tion in synovial thickness as assessed by high-resolution
ultrasound was 50% in the infliximab group, versus an
increase of 1.2% in the placebo group (P = 0.014). Simi-
larly, median color Doppler area diminished by 98.4% in
the infliximab group, versus a reduction of only 30.7% in
the placebo group, a statistically significant difference
(P = 0.017). The total number of vascularised erosions
decreased by a median of 1.0 in the infliximab group,
whereas there was no change from baseline in the
placebo group (P = 0.001). In this study, ultrasonographic
measures of joint vascularity were better able to discrimi-
nate between patients receiving infliximab and those
receiving placebo infusions than were changes in DAS28,
a composite measure of disease activity.
It has recently been shown that there is a very close rela-
tion between the presence or absence of vascular flow
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Figure 2
Relation between serum VEGF concentrations, measured at first
presentation in a cohort of patients with early RA, and joint damage
over the following year, expressed as change in the van der Heijde
modification of the Sharp score. Original data reported in [36]. 
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Combined high-resolution ultrasound and power Doppler imaging of a
metacarpophalangeal joint in RA, seen in longitudinal section. The red
colouring represents vascular signal and the arrow indicates a
vascularised erosion.S103
signal on power Doppler imaging and the rate of early
synovial enhancement on dynamic gadolinium-enhanced
magnetic resonance imaging (MRI) of RA metacarpo-
phalangeal joints [51]. The ability to distinguish between
RA joint effusion and synovial proliferation using MRI has
been greatly improved by the introduction of paramagnetic
contrast agents. The early, post-gadolinium synovial mem-
brane enhancement in RA joints, determined by dynamic
MRI, is considered to reflect synovial perfusion and per-
meability [52–54]. Histopathologic analyses of synovial
tissue samples obtained from arthrotomy or arthroscopic
or blind biopsies from knee joints after dynamic MRI
imaging indicate that vascular density and blood-vessel
fractional area correlate significantly with the early
enhancement rate of synovial membrane [54,55]. Dynamic
MRI with a gadolinium-based blood-pool agent has been
employed as a technique for measurement of abnormal
capillary permeability in synovial tissue of arthritic knees in
rabbits [56]. MRI-derived microvascular characteristics
comprising plasma volume, fractional leak rate, and per-
meability-surface area product correlated positively with
histologic findings.
A novel approach to detecting angiogenesis in vivo using
MRI has been described in a tumour model in rabbits. This
technique, using a paramagnetic contrast agent targeted
to endothelial αVβ3, an integrin expressed on new blood
vessels, by linkage to a monoclonal antibody, successfully
provided enhanced and detailed images of rabbit carcino-
mas and, furthermore, disclosed angiogenic ‘hot spots’
not visible by standard MRI [57].
Another approach to imaging RA synovial vasculature,
which has the disadvantage, relative to the previously
described methodologies, that it exposes patients to ionis-
ing radiation, is the use of radiolabelled peptides that bind
endothelium. For example, a radiolabelled F(ab)2 (antigen-
binding fragment) of a monoclonal antibody that recog-
nises an epitope of E-selectin has been successfully used
to image RA synovium [58] and a radiolabelled E-selectin
binding peptide has been used to image activated synovial
endothelium in rat adjuvant arthritis [59]. This is a particu-
larly attractive endothelial adhesion molecule to target,
because it is not constitutively expressed but instead is
synthesised  de novo in response to proinflammatory
cytokines and expressed on the luminal surface of the
endothelium, where it is readily accessible to circulating
radioligands [60]. Furthermore, the monoclonal antibody is
internalised as a result of receptor recycling, with very little
shedding into the general circulation. Nonetheless, positive
images of activated endothelium obtained with specific
proteins and peptides will inevitably include a component
due to nonspecific uptake [61]. Neovascular antigens in
inflammatory tissue are other potentially useful targets.
Although neovascularisation may be nonspecifically
imaged with technetium-labelled isonitriles [62], targeting
epitopes associated with αV integrins, which are specific
to new blood vessels [63,64], is a more attractive goal.
Relevance to the understanding of
pathogenesis
An inflamed synovium is central to the pathophysiology of
RA. Histologically, RA synovitis is characterised by a
mononuclear cell infiltrate and luxuriant vasculature [65].
Furthermore, the disease activity in a given joint is corre-
lated with the synovial vascularisation [66,67]. Angiogene-
sis can be evident on microscopic examination of synovial
biopsies from the earliest stages of disease evolution [68]
and is observed as a fine network of vessels over the
rheumatoid synovium at arthroscopic inspection of RA
joints. Angiogenesis is integral to the development of
inflammatory pannus, and without it, leukocyte ingress
could not occur. Furthermore, formation of new blood
vessels permits a supply of nutrients and oxygen to the
augmented inflammatory cell mass and so contributes to
the perpetuation of synovitis. Studies in experimental
models of arthritis suggest that destruction of bone and
cartilage may be more closely linked to angiogenesis than
to pannus swelling [69,70]. In patients with early RA, my
colleagues and I have observed a striking association
between the presence of bone erosion on high-resolution
ultrasound imaging of metacarpophalangeal joints and
increased intra-articular blood flow in power Doppler
mode imaging at the site of bone damage [48] These find-
ings implicate vascular pannus in joint destruction in early
RA and strongly support the contention that angiogenesis
is a potential target for therapy in this disease.
VEGF and angiogenesis as a target for therapy
It is interesting to note that many of the anti-rheumatic
drugs used in clinical practice have an effect on the vascu-
lature. Anti-rheumatic drugs including gold, bucillamine,
methotrexate, and corticosteroids inhibit production of
VEGF by cultured synoviocytes [35]. Methotrexate, at con-
centrations equivalent to those attained in the serum of RA
patients treated with this drug, inhibits basal and stimulated
endothelial proliferation in vitro [71]. Thiol-containing and
gold compounds may modulate neovascularisation indi-
rectly by inhibiting production of monocyte/macrophage-
derived angiogenic factors [72,73]. Cyclosporin A is
known to inhibit activity of transcription factors of the
nuclear factor of activated T-cells family. In addition,
cyclosporin A has recently been shown to inhibit migration
of primary endothelial cells and angiogenesis induced by
VEGF, a novel mechanism that may account for some of
the therapeutic activity of this drug in RA [74]. The effect
appears to be mediated through inhibition of cyclooxyge-
nase-2, the transcription of which is activated by VEGF in
primary endothelial cells. Diminished vascular permeability
consequent upon a reduction in VEGF is thought to be a
factor contributing to the rapid reduction of joint swelling
observed after anti-TNFα therapy [38]. We have shown
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that TNF blockade is also accompanied by reduced syn-
ovial angiogenesis as assessed by immunohistologic analy-
sis of microvascular density and expression of αVβ3
integrin in synovial biopsy tissue taken before and 4 weeks
after a single 10-mg/kg infliximab infusion [16].
Given the evidence discussed so far, there are strong
grounds on which to suggest that targeting the newly
formed vasculature of the RA pannus might modify
disease progression. Identification of new molecular
targets for immunotherapeutic intervention in RA ideally
requires evidence of synovial tissue expression of the mol-
ecule at relevant sites, in vitro evaluation of its biologic
function, and preclinical studies demonstrating clinical effi-
cacy in experimental models [75]. I have already dis-
cussed the first two of these three requirements in
considering angiogenesis, and molecules that promote it
such as VEGF, as targets for therapy in RA. However, the
third requirement, demonstration of clinical efficacy in
experimental models, would perhaps represent the most
convincing evidence in support of anti-angiogenic strate-
gies in the treatment of human disease.
In collagen-induced arthritis in rats, administration of the
anti-angiogenic agent AGM-1470 attenuates the clinical
severity of established disease, with reduction in serum
concentrations of VEGF [76] and histologic evidence of
marked inhibition of pannus formation and neovascularisa-
tion [77,78]. In murine collagen-induced arthritis, expres-
sion of biologically active VEGF was along a time course
that paralleled the expression of VEGFR-1 and VEGFR-2
[79]. Furthermore, in this model, concentrations of VEGF
expression correlated with clinical severity of disease and
degree of neovascularisation. Administration of anti-VEGF
antiserum before the onset of disease significantly delayed
the development and severity of arthritis, whereas adminis-
tration after disease onset had no effect on the progres-
sion or ultimate severity of the disease [79]. In another
study employing the murine collagen-induced arthritis
model, saline, normal rabbit immunoglobulin, or rabbit
polyclonal anti-human VEGF(121) antibodies were admin-
istered to mice either before or after the onset of clinical
disease [80]. Treatment with anti-VEGF antibodies before
disease onset significantly delayed the development of
arthritis and attenuated the severity of disease expression,
although the frequency of the occurrence of disease did
not differ from that in either control group. In this study,
improvement in clinical and histological parameters of
arthritis was observed even when anti-VEGF was adminis-
tered after the onset of disease. Another approach to
VEGF blockade in murine collagen-induced arthritis has
been to administer exogenous sFlt-1 linked to polyethyl-
ene glycol (sFlt-PEG) to increase its in vivo half-life. In this
model, daily intraperitoneal administration of this treatment
from the first day of clinical arthritis was reported to ame-
liorate the severity of clinical disease expression and of
bone and cartilage destruction on histopathological
assessment [81].
Other anti-angiogenic agents successfully used in preclini-
cal animal studies include the fungal derivative TNP-470
and specific antagonists of αVβ3. In a transgenic rodent
model of inflammatory arthritis, administration of TNP-470
attenuated development of arthritis and alleviated clinical
signs if administered at the early stages of clinical disease.
Clinical improvement was associated with reduced carti-
lage and bone destruction [82]. There are preclinical in
vivo data showing that selective targeting of new blood
vessels may result in modification of disease. Intra-articular
injections of specific antagonists of αVβ3 resulted in
reduced synovial vascularity in rabbits after induction of
arthritis with joint injections of a combination of ovalbumin
and basic fibroblast growth factor. Diminished synovial vas-
cularity was associated with a significant decrease in all
arthritic parameters, including joint swelling and synovitis.
Of note, the beneficial effects of angiogenesis inhibition
were apparent in the established phase of disease [70].
Similarly, symptoms of adjuvant-induced arthritis in rats are
significantly reduced by prophylactic or therapeutic admin-
istration of an orally active αVβ3 antagonist, with significant
improvements in joint integrity seen on MRI [83].
What does the future hold in angiogenesis
modulation and imaging of vasculature?
Given the central role played by angiogenesis and VEGF
in arthritic disease, it might be predicted that suppression
of angiogenesis and/or VEGF activity will be an effective
treatment strategy in RA. However, it is possible that such
an approach will be limited by toxicities related to inhibi-
tion of physiological processes involving VEGF-mediated
angiogenesis. Examples include wound healing, the
female reproductive cycle, and maintenance of cardiovas-
cular health. Data arising from ongoing clinical trials of
anti-angiogenic agents in the treatment of cancers should
give valuable insight as to whether these theoretical con-
cerns are well founded or not.
Studies evaluating new imaging technologies suggest that
clinical joint examination and plain radiography are rela-
tively insensitive [84] and may thus be insufficient mea-
sures for use in future clinical trials designed to assess
reduction in symptoms and signs of rheumatoid disease
as well as retardation of structural damage to joints. In a
double-blind study in early RA in which patients received
either infliximab or placebo infusions added to pre-existing,
stable methotrexate therapy, my colleagues and I have
recently shown that measurement of changes in serum
VEGF concentration and ultrasonographic assessments of
changes in synovial vascularity are able to discriminate
between patients receiving either infliximab or placebo
infusions [50]. We have also reported that the serum
VEGF concentration at first presentation in early RA signif-
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icantly correlates with radiological progression over the
following year [36]. These findings predict that imaging
technologies capable of evaluating synovial vascularity will
have a practical value in determining prognosis and in
assessment of response to therapy. Of the technologies
discussed in this chapter, ultrasonographic imaging
methods have the advantage that they are noninvasive,
involve no ionising radiation, and are both more widely
available and more economical than MRI. Furthermore,
rheumatologists can be trained to undertake ultrasono-
graphic imaging, thus obviating the delay incurred in refer-
ral to a radiologist.
Concluding remarks
VEGF concentrations are elevated in the serum of patients
with RA and correlate with individual and composite mea-
sures of the disease activity. Sensitive, noninvasive
methods for visualising synovial vascularisation in RA,
such as power Doppler sonography, are emerging as clini-
cally important tools in the assessment of disease activity
and hold promise as novel means of evaluating the
response of patients to therapy. As arresting structural
damage to joints becomes a realistic goal in the manage-
ment of RA, vascular imaging and serologic markers may
be more sensitive than disease activity scores in determin-
ing at an early stage of treatment which patients are
responding satisfactorily.
Glossary of terms
Flt-1 = fms-like tyrosine kinase receptor-1, or VEGF recep-
tor-1 (VEGFR-1); KDR = kinase-insert-domain-containing
receptor, or VEGF receptor-2 (VEGFR-2); sFlt-1 = soluble
Flt-1; VEGFR = vascular endothelial growth factor receptor.
References
1. Sharp JT, Wolfe F, Mitchell DM, Bloch DA: The progression of
erosion and joint space narrowing scores in rheumatoid
arthritis during the first twenty-five years of disease. Arthritis
Rheum 1991, 34:660-668. [archival research]
2. Maini RN, Taylor PC: Anti-cytokine therapy in rheumatoid
arthritis. Ann Rev Med 2000, 51:207-229. [key review]
3. Taylor PC: Anti-TNF therapies. Curr Opin Rheumatol 2001, 13:
164-169. [key review]
4. Desmouliere A, Redard M, Darby I, Gabbiani G: Apoptosis medi-
ates the decrease in cellularity during the transition between
granuloma tissue and scar. Am J Pathol 1995,  146:56-66.
[archival research]
5. Walsh DA: Angiogenesis and arthritis. Rheumatology (Oxford)
1999, 38:103-112. [key review]
6. Koch A: Angiogenesis: implications for rheumatoid arthritis.
Arthritis Rheum 1998, 41:951-962. [key review]
7. Paleolog EM, Fava RA: Angiogenesis in rheumatoid arthritis:
implications for future therapeutic strategies. Springer Semin
Immunopathol 1998, 20:73-94. [key review]
8. Paleolog EM, Miotla JM: Angiogenesis in arthritis: role in
disease pathogenesis and as a potential therapeutic target.
Angiogenesis 1998, 2:295-307. [key review]
9. Jain A, Nanchahal J, Troeberg L, Green P, Brennan F: Production
of cytokines, vascular endothelial growth factor, matrix metal-
loproteinases, and tissue inhibitor of metalloproteinases 1 by
tenosynovium demonstrates its potential for tendon destruc-
tion in rheumatoid arthritis. Arthritis Rheum 2001,  44:1754-
1760. [general reference]
10. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM,
Dvorak HF: Vascular permeability factor/vascular endothelial
growth factor: a multifunctional angiogenic cytokine. EXS
1997, 79:233-269. [key review]
11. Achen MG, Stacker SA: The vascular endothelial growth factor
family; proteins which guide the development of the vascula-
ture. Int J Exp Pathol 1998, 79:255-265. [general reference]
12. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular
endothelial growth factor (VEGF) and its receptors. FASEB J
1999, 13:9-22. [general reference]
13. Ferrara N: The role of vascular endothelial growth factor in
pathological angiogenesis. Breast Cancer Res Treat 1995, 36:
127-137. [archival research]
14. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B,
Jackman RW, Senger DR, Dvorak HF, Brown LF: Vascular per-
meability factor/endothelial growth factor (VPF/VEGF): accu-
mulation and expression in human synovial fluids and
rheumatoid synovial tissue. J Exp Med 1994,  180:341-346.
[archival research]
15. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong
WL, Pope RM, Ferrara N: Vascular endothelial growth factor. A
cytokine modulating endothelial function in rheumatoid arthri-
tis. J Immunol 1994, 152:4149-4156. [archival research]
16. Taylor PC, Patel S, Paleolog E, McCloskey RV, Feldmann M, Maini
RN: Reduced synovial vascularity following TNFα α blockade in
rheumatoid arthritis [abstract]. Arthritis Rheum 1998,
41(suppl):S295. [general reference]
17. Kasama T, Shiozawa F, Kobayashi K, Yajima N, Hanyuda M,
Takeuchi HT, Mori Y, Negishi M, Ide H, Adachi M: Vascular
endothelial growth factor expression by activated synovial
leukocytes in rheumatoid arthritis: critical involvement of the
interaction with synovial fibroblasts. Arthritis Rheum 2001, 44:
2512-2524. [general reference]
18. Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E: Expression of
vascular endothelial growth factor isoforms and their recep-
tors Flt-1, KDR, and neuropilin-1 in synovial tissues of
rheumatoid arthritis. J Pathol 2000, 191:426-433. [general ref-
erence]
19. Pufe T, Petersen W, Tillmann B, Mentlein R: Splice variants
VEGF121 and VEGF165 of the angiogenic peptide vascular
endothelial cell growth factor are expressed in the synovial
tissue of patients with rheumatoid arthritis. J Rheumatol 2001,
28:1482-1485. [general reference]
20. Giatromanolaki A, Sivridis E, Athanassou N, Zois E, Thorpe PE,
Brekken RA, Gatter KC, Harris AL, Koukourakis IM, Koukourakis
MI:  The angiogenic pathway “vascular endothelial growth
factor/flk-1(KDR)-receptor” in rheumatoid arthritis and
osteoarthritis. J Pathol 2001, 194:101-108. [general reference]
21. Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F, Fava
RA: Hypoxia augments cytokine (transforming growth factor-
beta (TGF-beta) and IL-1-induced vascular endothelial growth
factor secretion by human synovial fibroblasts. Clin Exp
Immunol 1999, 115:176-182. [general reference]
22. Taylor PC, Miotla JM, Etherington P, Winlove P, Young S, Pale-
olog E, Maini RN: VEGF release is associated with hypoxia in
inflammatory arthritis [abstract]. Rheumatology (Oxford) 2000,
40(suppl):S7. [general reference]
23. Stevens CR, Blake DR, Merry P, Revell PA, Levick JR: A compar-
ative study by morphometry of the microvasculature in
normal and rheumatoid synovium. Arthritis Rheum 1991, 34:
1508-1513. [general reference]
24. Richard DE, Berra E, Pouyssegur J: Angiogenesis: how a tumor
adapts to hypoxia. Biochem Biophys Res Commun 1999, 266:
718-722. [general reference]
25. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks
KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ,
Maxwell PH: Induction of endothelial PAS domain protein-1 by
hypoxia: characterisation and comparison with hypoxia-
inducible factor-1 alpha. Blood 1998, 92:2260-2268. [general
reference]
26. Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD: Expression of
vascular endothelial growth factor in synovial fibroblasts is
induced by hypoxia and and interleukin 1beta. J Rheumatol
1997, 24:1253-1259. [general reference]
27. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E,
Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M,
Matsuo K, Tanikawa K: Vascular endothelial growth factor in
Available online http://arthritis-research.com/content/4/S3/S099S106
patients with rheumatoid arthritis. Scand J Rheumatol 1998,
27:377-380. [general reference]
28. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K: Serum
concentrations of vascular endothelial growth factor in colla-
gen diseases. Br J Dermatol 1998, 139:1049-1051. [general ref-
erence]
29. Bottomley MJ, Webb NJ, Watson CJ, Holt PJ, Freemont AJ,
Brenchley PE: Peripheral blood mononuclear cells from
patients with rheumatoid arthritis spontaneously secrete vas-
cular endothelial growth factor (VEGF): specific up-regulation
by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid.
Clin Exp Immunol 1999, 117:171-176. [general reference]
30. Nagashima M, Yoshino S, Ishiwata T, Asano G: Role of vascular
endothelial growth factor in angiogenesis of rheumatoid arthritis. J
Rheumatol 1995, 22:1624-1630. [general reference]
31. Taichman N, Young S, Cruchley A, Taylor PC, Paleolog E: Human
neutrophils secrete vascular endothelial growth factor. J
Leukocyte Biol 1997, 62:397-400. [general reference]
32. Kasama T, Kobayashi K, Yajima N, Shiozawa F, Yoda Y, Takeuchi
HT, Mori Y, Negishi M, Ide H, Adachi M: Expression of vascular
endothelial growth factor by synovial fluid neutrophils in
rheumatoid arthritis (RA). Clin Exp Immunol 2000,  121:533-
538. [general reference]
33. Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, Cho CS, Kim
HY:  Vascular endothelial growth factor levels in the serum
and synovial fluid of patients with rheumatoid arthritis. Clin
Exp Rheumatol 2001, 19:321-324. [general reference]
34. Fraser A, Fearon U, Reece R, Emery P, Veale DJ: Matrix metallo-
proteinase 9, apoptosis, and vascular morphology in early
arthritis. Arthritis Rheum 2001,  44:2024-2028. [general refer-
ence]
35. Nagashima M, Wauke K, Hirano D, Ishigami S, Aono H, Takai M,
Sasano M, Yoshino S: Effects of combinations of anti-
rheumatic drugs on the production of vascular endothelial
growth factor and basic fibroblast growth factor in cultured
synoviocytes and patients with rheumatoid arthritis. Rheuma-
tology (Oxford) 2000, 39:1255-1262. [general reference]
36. Ballara S, Taylor PC, Reusch P Marme D, Maini RN, Paleolog E:
Serum vascular endothelial growth factor (VEGF) and soluble
VEGF receptor in inflammatory arthritis. Arthritis Rheum 2001,
44:2055-2064. [general reference]
37. Sone H, Sakauchi M, Takahashi A, Suzuki H, Inoue N, Iida K,
Shimano H, Toyoshima H, Kawakami Y, Okuda Y, Matsuo K,
Yamada N: Elevated levels of vascular endothelial growth
factor in the sera of patients with rheumatoid arthritis correla-
tion with disease activity. Life Sci 2001,  69:1861-1869.
[general reference]
38. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M,
Maini RN: Modulation of angiogenic vascular endothelial
growth factor (VEGF) by TNFα α and IL-1 in rheumatoid arthri-
tis. Arthritis Rheum 1998, 41:1258-1265. [general reference]
39. Kendall RL, Wang G, Thomas KA: Identification of a natural
soluble form of the vascular endothelial growth factor recep-
tor, FLT-1, and its heterodimerization with KDR. Biochem
Biophys Res Commun 1996, 226:324-328. [archival research]
40. Hornig C, Weich HA: Soluble VEGF receptors. Recombinant
and naturally occurring forms involved in the regulation of
angiogenesis. Angiogenesis 1999, 3:33-39. [general reference]
41. van der Heijde D: How to read radiographs according to the
Sharp/van der Heijde method. J Rheumatol 2000, 27:261-263.
[general reference]
42. Newman JS, Laing TJ, McCarthy CJ, Adler RS: Power Doppler
sonography of synovitis: assessment of therapeutic response
– preliminary observations. Radiology 1996,  198:582-584.
[archival research]
43. Hau M, Schultz H, Tony HP, Keberle M, Jahns R, Haerten R,
Jenett M: Evaluation of pannus and vascularization of the
metacarpophalangeal and proximal interphalangeal joints in
rheumatoid arthritis by high-resolution ultrasound (multidi-
mensional linear array). Arthritis Rheum 1999, 42:2303-2308.
[general reference]
44. Schmidt WA, Volker L, Zacher J, Schlafke M, Ruhnke M, Grom-
nica-Ihle E: Colour Doppler ultrasonography to detect pannus
in knee joint synovitis. Clin Exp Rheum 2000,  18:439-444.
[general reference]
45. Walther M, Harms H, Krenn V, Radke S, Faehndrich TP, Gohlke F:
Correlation of power Doppler sonography with vascularity of
the synovial tissue of the knee joint in patients with
osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2001,
44:331-338. [general reference]
46. Giovagnorio F, Martinoli C, Coari G: Power Doppler sonography
in knee arthritis—a pilot study. Rheumatol Int 2001,  20:101-
104. [general reference]
47. Qvistgaard E, Rogind H, Torp-Pedersen S, Terslev L, Danneskiold-
Samsoe B, Bliddal H: Quantitative ultrasonography in rheuma-
toid arthritis: evaluation of inflammation by Doppler technique.
Ann Rheum Dis 2001, 60:690-693. [general reference]
48. Steuer A, Blomley M. Cosgrove D, Maini RN, Taylor PC: Com-
bined power colour doppler and greyscale ultrasound demon-
strate an association between vascularity and erosion in
rheumatoid arthritis [abstract]. Arthritis Rheum 2000,  43
(suppl):S292. [general reference]
49. Ferrel WR, Balint PV, Egan CG, Lockhart JC, Sturrock RD:
Metacarpophalangeal joints in rheumatoid arthritis: laser
Doppler imaging – initial experience. Radiology 2001,  220:
257-262. [general reference]
50. Taylor PC, Steuer A, Charles P, Gruber J, Cosgrove D, Blomley M,
Wagner C, Marsters P, DeWoody K, Maini RN. Early RA patients
on infliximab therapy show significant changes in sono-
graphic measures of joint vascularity and serum VEGF by 18
weeks [abstract]. Arthritis Rheum 2001,  44(suppl):S152
[general reference]
51. Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen
T, Ostergaard M: Power Doppler ultrasonongraphy for assess-
ment of synovitis in the metacarpophalangeal joints of
patients with rheumatoid arthritis; a comparison with dynamic
magnetic resonance imaging. Arthritis Rheum 2001, 44:2018-
2023. [general reference]
52. Konig H, Sieper J, Wolf KJ: Rheumatoid arthritis: evaluation of
hypervascular and fibrous pannus with dynamic MR imaging
enhanced with Gd-DTPA. Radiology 1990,  176:473-477.
[archival research]
53. Gaffney K, Cookson J, Blake D, Coumbe A, Blades S: Quantifica-
tion of rheumatoid synovitis by magnetic resonance imaging.
Arthritis Rheum 1995, 38:1610-1617. [archival research]
54. Gaffney K, Cookson J, Blades S, Coumbe A, Blake D: Quantita-
tive assessment of the rheumatoid synovial microvascular
bed by gadolinium-DTPA enhanced magnetic resonance
imaging. Ann Rheum Dis 1998, 57:152-157. [general reference]
55. Ostergaard M, Stoltenberg M, Lovgreen-Nielsen P, Volck B,
Sonne-Holm S, Lorenzen I: Quantification of synovitis by MRI:
correlation between dynamic and static gadolinium-enhanced
magnetic resonance imaging and microscopic and macro-
scopic signs of synovial inflammation. Magn Reson Imaging
1998, 16:743-754. [general reference]
56. van Dijke CF, Peterfy CG, Brasch RC, Lang P, Roberts TP,
Shames D, Kneeland JB, Lu Y, Mann JS, Kapila SD, Genant HK:
MR imaging of the arthritic rabbit knee joint using albumin-
(Gd-DTPA)30 with correlation to histopathology. Magn Reson
Imaging 1999, 17:237-245. [general reference]
57. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li
KC: Detection of tumor angiogenesis in vivo by alphaVbeta3-
targeted magnetic resonance imaging. Nat Med 1998, 4:623-
626. [general reference]
58. Chapman PT, Jamar F, Keelan ETM, Peters AM, Haskard DO: Use
of a radiolabeled monoclonal antibody against E-selectin for
imaging of endothelial activation in rheumatoid arthritis.
Arthritis Rheum 1996, 39:1371-1375. [archival research]
59. Zinn KR, Chaudhuri TR, Smyth CA, Wu Q, Liu HG, Fleck M,
Mountz JD, Mountz JM: Specific targeting of activated endothe-
lium in rat adjuvant arthritis with a 99mTc-radiolabeled E-
selectin-binding peptide. Arthritis Rheum 1999,  42:641-649.
[general reference]
60. Keelan ET, Licence ST, Peters AM, Binns RM, Haskard DO:
Characterization of E-selectin expression in vivo with use of a
radiolabeled monoclonal antibody. Am J Physiol 1994,  266:
H278-290. [archival research]
61. Jamar F, Chapman PT, Manicourt DH, Glass DM, Haskard DO,
Peters AM: A comparison between 111In-anti-E-selectin mAb
and 99Tcm-labelled human non-specific immunoglobulin in
radionuclide imaging of rheumatoid arthritis. Br J Radiol 1997,
70:473-481. [general reference]
62. Scopinaro F, Schillaci O, Scarpini M, Mingazzini PL, Di Macio L,
Banci M, Danieli R, Zerilli M, Limiti MR, Centi Colella A: Tech-
Arthritis Research    Vol 4 Suppl 3 TaylorS107
netium-99m sestamibi: an indicator of breast cancer invasive-
ness. Eur J Nucl Med 1994, 21:984-987. [archival research]
63. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T,
Klier G, Cheresh DA: Integrin α αVβ β3 antagonists promote tumor
regression by inducing apoptosis of angiogenic blood
vessels. Cell 1994, 79:1157-1164. [archival research]
64. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA,
Cheresh DA: Definition of two angiogenic pathways by distinct
α αV integrins. Science 1995, 270:1500-1502. [archival research]
65. FitzGerald O, Bresnihan B: Synovial membrane cellularity and
vascularity. Ann Rheum Dis 1995,  54:511-515. [archival
research]
66. Lindblad S, Hedfors E: Intraarticular variation in synovitis. Local
macroscopic and microscopic signs of inflammatory activity
are significantly correlated. Arthritis Rheum 1985, 28:977-986.
[archival research]
67. Ostergaard M, Hansen M, Stoltenberg M, Gideon P, Klarland M,
Jensen KE, Lorenzen I: Magnetic resonance imaging-deter-
mined synovial membrane volume as a marker of disease
activity and a predictor of progressive joint destruction in the
wrists of patients with rheumatoid arthritis. Arthritis Rheum
1999, 42:918-929. [general reference]
68. Hirohata S, Sakakibara J: Angioneogenesis as a possible
elusive trigger factor in rheumatoid arthritis [letter]. Lancet
1999, 353:1331. [general reference]
69. Firestein GS: Starving the synovium: angiogenesis and inflam-
mation in rheumatoid arthritis. J Clin Invest 1999, 103:3-4. [key
review]
70. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI,
Cheresh D: Decreased angiogenesis and arthritic disease in
rabbits treated with alphavbeta3 antagonist. J Clin Invest
1999, 103:47-54. [general reference]
71. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K: Inhibition
of  in vitro vascular endothelial cell proliferation and in vivo
neovascularization by low-dose methotrexate. Arthritis Rheum
1989, 32:1065-1073. [archival research]
72. Koch AE, Cho M, Burrows J, Leibovich SJ, Polverini PJ: Inhibition
of production of macrophage-derived angiogenic activity by
the anti-rheumatic agents gold sodium thiomalate and aura-
nofin. Biochem Biophys Res Commun 1988,  154:205-212.
[archival research]
73. Koch AE, Burrows JC, Polverini PJ, Cho M, Leibovich SJ: Thiol-
containing compounds inhibit the production of
monocyte/macrophage-derived angiogenic activity. Agents
Actions 1991, 34:350-357. [archival research]
74. Hernandez GL, Volpert OV, Iniguez MA, Lorenzo E, Martinez-Mar-
tinez S, Grau R, Fresno M, Redondo JM: Selective inhibition of
vascular endothelial growth factor-mediated angiogenesis by
cyclosporin A: roles of the nuclear factor of activated T cells
and cyclooxygenase 2. J Exp Med 2001, 193:607-620. [general
reference]
75. Taylor PC, Williams RO, Maini RN: Immunotherapy for rheuma-
toid arthritis. Curr Opin Immunol 2001, 13:611-616. [key review]
76. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E: Suppression of
collagen-induced arthritis by an angiogenesis inhibitor, AGM-
1470, in combination with cyclosporin: reduction of vascular
endothelial growth factor (VEGF). Cell Immunol 1995,  166:
196-206. [archival research]
77. Peacock DJ, Banquerigo ML, Brahn E: Angiogenesis inhibition
suppresses collagen arthritis. J Exp Med 1992,  175:1135-
1138. [archival research]
78. Oliver SJ, Banquerigo ML, Brahn E: Suppression of collagen-
induced arthritis using an angiogenesis inhibitor, AGM-1470,
and a microtubule stabilizer, taxol. Cell Immunol 1994, 157:
291-299. [archival research]
79. Lu J, Kasama T, Kobayashi K, Yoda Y, Shiozawa F, Hanyuda M,
Negishi M, Ide H, Adachi M: Vascular endothelial growth factor
expression and regulation of murine collagen-induced arthri-
tis. J Immunol 2000, 164:5922-5927. [general reference]
80. Sone H, Kawakami Y, Sakauchi M, Nakamura Y, Takahashi A,
Shimano H, Okuda Y, Segawa T, Suzuki H, Yamada N: Neutral-
ization of vascular endothelial growth factor prevents colla-
gen-induced arthritis and ameliorates established disease in
mice. Biochem Biophys Res Commun 2001,  281:562-568.
[general reference]
81. Miotla JM, Maciewicz R, Kendrew J, Feldmann M, Paleolog E:
Treatment with soluble VEGF receptor reduces disease
severity in murine collagen-induced arthritis. Lab Invest 2000,
80:1195-1205. [general reference]
82. de Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M,
Gougerot-Pocidalo MA, Gaudry M. Suppression of arthritis and
protection from bone destruction by treatment with TNP-
470/AGM-1470 in a transgenic mouse model of rheumatoid
arthritis. Arthritis Rheum 2000,  43:2056-2063. [general refer-
ence]
83. Badger AM, Blake S, Kapadia R, Sarkar S, Levin J, Swift BA,
Hoffman SJ, Stroup GB, Miller WH, Gowen M, Lark MW:
Disease-modifying activity of SB 273005, an orally active, non-
peptide alphavbeta3 (vitronectin receptor) antagonist, in rat
adjuvant-induced arthritis. Arthritis Rheum 2001, 44:128-137.
[general reference]
84. Wakefield RJ, Gibbon WW, Conaghan PG, O’Connor P, McGo-
nagle D, Pease C, Green MJ, Veale DJ, Isaacs JD, Emery P: The
value of sonography in the detection of bone erosions in
patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:
2762 –2770. [general reference]
Available online http://arthritis-research.com/content/4/S3/S099